S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

EPRX Eupraxia Pharmaceuticals Inc

2.8957

-0.1043 (-3.48%)

Jan 31 2025 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

Eupraxia Pharmaceuticals Inc News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 20 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Wednesday 20 November 2024 (2 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Thursday 14 November 2024 (3 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 13 November 2024 (3 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Wednesday 13 November 2024 (3 months ago) • PR Newswire (Canada)

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Tuesday 12 November 2024 (3 months ago) • PR Newswire (US)

Form D - Notice of Exempt Offering of Securities
Friday 8 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Thursday 7 November 2024 (3 months ago) • PR Newswire (US)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Thursday 7 November 2024 (3 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Thursday 31 October 2024 (3 months ago) • PR Newswire (US)

More Eupraxia Pharmaceuticals Inc News Articles

Xtrackers MSCI Europe ES...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions